Bukwang receives marketing approval in the Philippines
Published: 2009-03-10 06:57:00
Updated: 2009-03-10 06:57:00
Bukwang Pharm says the Philippines health authorities have recently granted its market approval to clevudine, an oral, once-daily pyrimidine nucleoside analog that was previously evaluated in 14 clinical trials in more than 800 individuals.
Under the agreement with Bukwang, the Japanese drug m...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
